HARBIN, China, Nov. 22, 2010 /PRNewswire-Asia-FirstCall/ --
Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT)
("Weikang" or the "Company"), a leading developer, manufacturer and
marketer of Traditional Chinese Medicine (TCM), Western
prescription and OTC pharmaceuticals and other health and
nutritional products in the People's
Republic of China, today announced it has added three new
sales agents in southwest and south central China.
Weikang has signed two provincial agent contracts and one
municipal agent contract in Guangxi, Hunan and Xiangtan. The new sales agents
began working with Weilang at the beginning of October and have
already contributed to RMB 9 million
yuan or $1.4 million in sales to
fourth quarter 2010 revenue. The two provincial contracts are
expected to add RMB 40 million or
$6 million each to annual sales
and the municipal contract is expected to add RMB 20 million or $3
million in annual sales. The products will be
sold through a variety of retail outlets including pharmacies
and nutritional stores.
"We are excited to expand our sales network by adding three new
sales agents, bringing our total number of agents to eight.
The new agents will be instrumental in expanding sales of our
new therapeutics in southwest and south central China," commented Mr. Yin Wang, Chairman and CEO of Weikang
Bio-Technology Group. "We will work closely with the new
agents providing them the marketing tools and education to be
successful in achieving their sales goals."
About Weikang Bio-Technology Group Co., Inc.
Weikang Bio-Technology Group Co., Inc. is principally engaged in
developing, manufacturing and distributing Traditional Chinese
Medicine (TCM), and health and nutritional supplements in
China, in compliance with
requisite Chinese licenses and approvals. The Company is also
expanding its business scope to develop, manufacture and distribute
Chinese herbal extract products and GMP certified western
prescription and OTC pharmaceuticals through its acquisition of
Tianfang. For more information, please visit
http://www.weikangbio.com.
Safe Harbor Statement
Certain statements in this press release constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. These forward-looking statements are often identified
by the use of forward-looking terminology such as "believes,"
"expects" or similar expressions, involve known and unknown risks
and uncertainties. Although the Company believes that the
expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of
factors, including those discussed in the Company's periodic
reports that are filed with the Securities and Exchange Commission
and available on its website (http://www.sec.gov). All
forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by
these factors. Other than as required under the securities laws,
the Company does not assume a duty to update these forward-looking
statements.
Investors Relation
contacts:
|
|
John Marco, Partner, Elite
IR
|
|
Tel:
+1-310-819-2948
|
|
Email: John.marco@elite-ir.com
|
|
|
|
Leslie J. Richardson, Partner,
Elite IR
|
|
Tel:
+852-3183-0283
|
|
Email: Leslie.richardson@elite-ir.com
|
|
|
SOURCE Weikang Bio-Technology Group Co., Inc.